Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy

Authors: Sofie De Langhe, Thomas Mulliez, Liv Veldeman, Vincent Remouchamps, Annick van Greveling, Monique Gilsoul, Eline De Schepper, Kim De Ruyck, Wilfried De Neve, Hubert Thierens

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

After breast-conserving radiation therapy most patients experience acute skin toxicity to some degree. This may impair patients’ quality of life, cause pain and discomfort. In this study, we investigated treatment and patient-related factors, including genetic polymorphisms, that can modify the risk for severe radiation-induced skin toxicity in breast cancer patients.

Methods

We studied 377 patients treated at Ghent University Hospital and at ST.-Elisabeth Clinic and Maternity in Namur, with adjuvant intensity modulated radiotherapy (IMRT) after breast-conserving surgery for breast cancer. Women were treated in a prone or supine position with normofractionated (25 × 2 Gy) or hypofractionated (15 × 2.67 Gy) IMRT alone or in combination with other adjuvant therapies. Patient- and treatment-related factors and genetic markers in regulatory regions of radioresponsive genes and in LIG3, MLH1 and XRCC3 genes were considered as variables. Acute dermatitis was scored using the CTCAEv3.0 scoring system. Desquamation was scored separately on a 3-point scale (0-none, 1-dry, 2-moist).

Results

Two-hundred and twenty patients (58%) developed G2+ dermatitis whereas moist desquamation occurred in 56 patients (15%). Normofractionation (both p < 0.001), high body mass index (BMI) (p = 0.003 and p < 0.001), bra cup size ≥ D (p = 0.001 and p = 0.043) and concurrent hormone therapy (p = 0.001 and p = 0.037) were significantly associated with occurrence of acute dermatitis and moist desquamation, respectively. Additional factors associated with an increased risk of acute dermatitis were the genetic variation in MLH1 rs1800734 (p=0.008), smoking during RT (p = 0.010) and supine IMRT (p = 0.004). Patients receiving trastuzumab showed decreased risk of acute dermatitis (p < 0.001).

Conclusions

The normofractionation schedule, supine IMRT, concomitant hormone treatment and patient related factors (high BMI, large breast, smoking during treatment and the genetic variation in MLH1 rs1800734) were associated with increased acute skin toxicity in patients receiving radiation therapy after breast-conserving surgery. Trastuzumab seemed to be protective.
Literature
1.
Early Breast Canc Trialists C: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011, 378 (9804): 1707-1716.CrossRef
2.
Feight D, Baney T, Bruce S, McQuestion M: Putting evidence into practice: evidence-based interventions for radiation dermatitis. Clin J Oncol Nurs. 2011, 15 (5): 481-492. 10.1188/11.CJON.481-492.CrossRefPubMed
3.
Tanteles GA, Whitworth J, Mills J, Peat I, Osman A, McCann GP, Chan S, Barwell JG, Talbot CJ, Symonds RP: Can cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer?. Br J Cancer. 2009, 101 (3): 403-409. 10.1038/sj.bjc.6605182.CrossRefPubMedPubMedCentral
4.
Lilla C, Ambrosone CB, Kropp S, Helmbold I, Schmezer P, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J: Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat. 2007, 106 (1): 143-150. 10.1007/s10549-006-9480-9.CrossRefPubMed
5.
Keller LMM, Sopka DM, Li TY, Klayton T, Li JS, Anderson PR, Bleicher RJ, Sigurdson ER, Freedman GM: Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the fox chase cancer center experience. Int J Radiat Oncol Biol Phys. 2012, 84 (4): 881-887. 10.1016/j.ijrobp.2012.01.069.CrossRefPubMed
6.
Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, Vu TTT, Truong P, Ackerman I, Paszat L: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008, 26 (13): 2085-2092. 10.1200/JCO.2007.15.2488.CrossRefPubMed
7.
Freedman GM, Anderson PR, Li JS, Eisenberg DF, Hanlon AL, Wang L, Nicolaou N: Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol-Cancer Clinical Trials. 2006, 29 (1): 66-70.CrossRef
8.
Moody AM, Mayles WPM, Bliss JM, Ahern RP, Owen JR, Regan J, Broad B, Yarnold JR: The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol. 1994, 33 (2): 106-112. 10.1016/0167-8140(94)90063-9.CrossRefPubMed
9.
Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, Davidson S, Dunning AM, Mills J, Murray RJS, Popanda O, Seibold P, West CML, Yarnold JR, Symonds RP: A replicated association between polymorphisms near TNF alpha and risk for adverse reactions to radiotherapy. Br J Cancer. 2012, 107 (4): 748-753. 10.1038/bjc.2012.290.CrossRefPubMedPubMedCentral
10.
Kim JH, Kolozsvary AJJ, Jenrow KA, Brown SL: Mechanisms of radiation-induced skin injury and implications for future clinical trials. Int J Radiat Biol. 2013, 89 (5): 311-318. 10.3109/09553002.2013.765055.CrossRefPubMed
11.
Rosenstein BS: Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics. 2011, 12 (2): 267-275. 10.2217/pgs.10.186.CrossRefPubMedPubMedCentral
12.
Murray RJS, Tanteles GA, Mills J, Perry A, Peat I, Osman A, Chan S, Cheung KL, Chakraborti PR, Woodings PL, Barwell JG, Symonds RP, Talbot CJ: Association between single nucleotide polymorphisms in the DNA repair gene LIG3 and acute adverse skin reactions following radiotherapy. Radiother Oncol. 2011, 99 (2): 231-234. 10.1016/j.radonc.2011.05.007.CrossRefPubMed
13.
Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Sho K, Omura M, Sekiguchi K, Kikuchi Y, Michikawa Y, Noda S, Sagara M, Ohashi J, Yoshinaga S, Mizoe J, Tsuiti H, Iwakawa M, Imai T: Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2007, 69 (3): 685-693. 10.1016/j.ijrobp.2007.06.021.CrossRefPubMed
14.
Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thierens H: Acute normal tissue reactions in head-and-neck cancer patients treated with Imrt: influence of dose and association with genetic polymorphisms in DNA Dsb repair genes. Int J Radiat Oncol Biol Phys. 2009, 73 (4): 1187-1195. 10.1016/j.ijrobp.2008.08.073.CrossRefPubMed
15.
Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM: Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet. 2008, 45 (3): 142-146.CrossRefPubMed
16.
Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG: Genetic analysis of radiation-induced changes in human gene expression. Nature. 2009, 459 (7246): 587-U120. 10.1038/nature07940.CrossRefPubMedPubMedCentral
17.
Mulliez T, Speleers B, Madani I, De Gersem W, Veldeman L, De Neve W: Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT?. Radiat Oncol. 2013, 8: 151-10.1186/1748-717X-8-151.CrossRefPubMedPubMedCentral
18.
Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DAL, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR, Start Trialists G: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008, 371 (9618): 1098-1107.CrossRefPubMed
19.
Mulliez T, Veldeman L, van Greveling A, Speleers B, Sadeghi S, Berwouts D, Decoster F, Vercauteren T, De Gersem W, Van den Broecke R, De Neve W: Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial comparing prone and supine positions. Radiother Oncol. 2013, 108 (2): 203-208. 10.1016/j.radonc.2013.08.040.CrossRefPubMed
20.
Remouchamps VM, Vicini FA, Sharpe MB, Kestin LL, Martinez AA, Wong JW: Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys. 2003, 55 (2): 392-406. 10.1016/S0360-3016(02)04143-3.CrossRefPubMed
21.
22.
James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP: Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev. 2010, CD003860-11
23.
Hannan R, Thompson RF, Chen Y, Bernstein K, Kabarriti R, Skinner W, Chen CC, Landau E, Miller E, Spierer M, Hong L, Kalnicki S: Hypofractionated whole-breast radiation therapy: does breast size matter?. Int J Radiat Oncol Biol Phys. 2012, 84 (4): 894-901. 10.1016/j.ijrobp.2012.01.093.CrossRefPubMed
24.
Corbin KS, Dorn PL, Jain SK, Al-Hallaq HA, Hasan Y, Chmura SJ: Hypofractionated radiotherapy does not increase acute toxicity in large-breasted women: results from a prospectively collected series. Am J Clin Oncol. 2014, 37 (4): 322-326. 10.1097/COC.0b013e31827b45b7.CrossRefPubMed
25.
Goldsmith C, Haviland J, Tsang Y, Sydenham M, Yarnold J, Grp FT: Large breast size as a risk factor for late adverse effects of breast radiotherapy: Is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?. Radiother Oncol. 2011, 100 (2): 236-240. 10.1016/j.radonc.2010.12.012.CrossRefPubMed
26.
Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE: The cambridge breast intensity-modulated radiotherapy trial: patient- and treatment-related factors that influence late toxicity. Clin Oncol. 2011, 23 (10): 662-673. 10.1016/j.clon.2011.04.011.CrossRef
27.
Dorn PL, Corbin KS, Al-Hallaq H, Hasan Y, Chmura SJ: Feasibility and acute toxicity of hypofractionated radiation in large-breasted patients. Int J Radiat Oncol Biol Phys. 2012, 83 (1): 79-83. 10.1016/j.ijrobp.2011.05.074.CrossRefPubMed
28.
Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NEA, Ozsahin M: Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 2010, 11 (3): 258-265. 10.1016/S1470-2045(10)70013-9.CrossRefPubMed
29.
Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA: Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009, 27 (16): 2638-2644. 10.1200/JCO.2008.17.9549.CrossRefPubMedPubMedCentral
30.
Whiffin N, Broderick P, Lubbe SJ, Pittman AM, Penegar S, Chandler I, Houlston RS: MLH1-93G > A is a risk factor for MSI colorectal cancer. Carcinogenesis. 2011, 32 (8): 1157-1161. 10.1093/carcin/bgr089.CrossRefPubMed
31.
Janko M, Ontiveros F, Fitzgerald TJ, Deng A, DeCicco M, Rock KL: IL-1 Generated subsequent to radiation-induced tissue injury contributes to the pathogenesis of radiodermatitis. Int J Radiat Oncol Biol Phys. 2012, 84 (3): S679-S679.CrossRef
Metadata
Title
Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy
Authors
Sofie De Langhe
Thomas Mulliez
Liv Veldeman
Vincent Remouchamps
Annick van Greveling
Monique Gilsoul
Eline De Schepper
Kim De Ruyck
Wilfried De Neve
Hubert Thierens
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-711

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

14-3-3σ induces heat shock protein 70 expression in hepatocellular carcinoma

Research article

The genetic basis for inactivation of Wnt pathway in human osteosarcoma

Research article

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

Research article

1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer

Research article

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

Research article

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits